Colon drug delivery
The use of amylose (and many amylose derivates) in targeted colon drug delivery systems have been studied for more than 25 years. This special functionality is attributable to the ability of amylose to resist enzymatic degradation in the upper intestines. In the colon, the amylose is microbiologically metabolized, thereby releasing the “trapped” pharmaceutical.
plantCarb founders have with success conducted researched on specially manufactured porous amylose granular as such passive drug delivery vehicles.
plantCarb’s ability to produce high volumes of amylose (95%) at extremely competitive cost levels effectively moves amylose-based drug delivery systems from use in only relatively rare diseases as e.g., Crohn’s disease, to high-volume market areas, e.g., standard antibiotics treatments, and food additives.
plantCarb now seek partnerships to exploit this exciting opportunity – contact us here.
No related publications found